Request Demo
Last update 24 Feb 2026
Dexrazoxane Hydrochloride
Last update 24 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 May 1995), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Australia) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
55
Clinical Trials associated with Dexrazoxane HydrochlorideNCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
NCT06262438
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
934
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Feb 2026JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
Dual protection by naringin and dexrazoxane against iron-induced erythrocyte damage: Exploring their synergistic regulation of ferroptosis and eryptosis
Article
Author: Bakheit, Ahmed H ; Alsegiani, Amsha S ; Attia, Sabry M ; Ahmad, Sheikh F ; Harisa, Gamaleldin I
Iron cellular accumulation is linked to ferroptosis, which induces cell injury. Conventional iron chelators often elicit side effects and encourage the exploration of naringin (NAR) as a potential protective agent against ferroptosis. Erythrocytes are a simple cellular model for exploring the beneficial effects of bioactive compounds. This study aims to investigate the protective effects of NAR against ferrous sulfate (FeSO4) induced ferroptosis. FeSO4 and hydrogen peroxide were applied to erythrocytes to induce ferroptosis either in the presence or absence of NAR, dexrazoxane (DEX), or their combination and compared to control cells. Key indicators of ferroptosis, including reactive oxygen species (ROS) production, GPX4 activity, glutathione (GSH) levels, malondialdehyde (MDA) levels, GPX4, GRD, and erythrocyte cytolysis, and eryptosis were analyzed using spectrophotometric and flow cytometric methods. Molecular docking studies with AutoDock Vina assessed the interactions between DEX, NAR, GPX4, GRD, HO-1, GST, SDH, AChE, and NOS. The present results displayed that both DEX and NAR significantly mitigates FeSO4-induced ROS production and lipid peroxidation while preserving GSH levels and enhancing GPX and GRD activities compared to the FeSO4-treated group. DEX and NAR also effectively prevented iron-induced erythrocyte cytolysis and eryptosis. The DEX and NAR combination produced pronounced effect of the measured parameters compared to other groups. Docking analysis indicated stronger binding affinities of NAR to GPX4, GRD, HO-1, GST, SDH, AChE, and NOS compared to DEX, suggesting NAR may be a more effective modulator. These findings concluded that NAR is a potential alternative to traditional DEX as iron chelators. Moreover, NAR is a promising therapy for disorders connected with iron overloading.
01 Feb 2026PEDIATRIC BLOOD & CANCER
Successful Treatment of Mediastinal Anthracycline Extravasation by Administration of Dexrazoxane
Letter
Author: Yamada, Ai ; Kuroki, Yota ; Moritake, Hiroshi ; Nagasawa, Shun
01 Feb 2026JACC-Basic to Translational Science
ICG-001 Provides Cardioprotection Against Doxorubicin-Induced Cardiotoxicity and Enhances Cancer Cytotoxicity
Article
Author: Meng, Fang ; Song, Yi ; Chen, Jack C H ; Sung, Chun C ; Deng, Ruixia ; Wu, Binbin ; Tsui, Stephen K W ; Liang, Yonghao ; Lam, Hin S ; Chan, Godfrey C F ; Poon, Ellen N ; Chan, Valerie T ; Ma, Chloe H Y ; Wang, Chi C ; Chung, Kenny K K ; Leung, Kam T ; Zhang, Tao ; Boheler, Kenneth R ; Kwok, Maxwell ; Tsoi, Chantelle
Doxorubicin is effective against cancer but can cause doxorubicin-induced cardiotoxicity (DCT). Drug discovery efforts against DCT are hampered by the need to balance cardioprotection and cancer control. This study demonstrates that ICG-001 suppressed DCT in patient-derived human induced pluripotent stem cell-derived cardiomyocytes in vitro and in mice in vivo, comparable to conventional treatment, dexrazoxane. Unlike dexrazoxane, ICG-001 was cytotoxic to cancer cells. Mechanistically, ICG-001 protected the mitochondria in cardiomyocytes via DPR1 inhibition, but suppressed cancer by repressing Wnt signaling. These dual mechanisms underscore the potential of ICG-001 as an adjunct treatment to doxorubicin to improve its safety and efficacy.
5
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | European Union | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Iceland | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Liechtenstein | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Norway | 27 Jul 2006 | |
| Cytoprotective Agent | China | 29 May 2006 | |
| Cardiomyopathies | United States | 26 May 1995 | |
| Metastatic breast cancer | United States | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | Denmark | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Germany | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Italy | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Netherlands | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Poland | 01 Apr 2002 | |
| Bronchitis | Phase 3 | Denmark | 01 Jun 2001 | |
| Cysts | Phase 2 | Spain | 21 Oct 2005 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 25 | (Dexrazoxane 100mg/m2) | ufshkufxsr = ffnnhtnxwo gebyfyonxe (ofkoayngrh, jexkhfqqem - gdzkoajpys) View more | - | 12 Jun 2025 | ||
(Dexrazoxane 200mg/m2) | ufshkufxsr = paqawhgtuo gebyfyonxe (ofkoayngrh, kfofenzrba - cautfyikpn) View more | ||||||
Phase 2 | 73 | (Arm 1: Doxorubicin and Upfront Dexrazoxane) | hirresnith(dakmbfnpsv) = ggdnjaauef zsywfatpik (qnpxhlwpvp, veufaorezk - pjtgoqxjsu) View more | - | 07 Nov 2023 | ||
(Arm 2: Control (Doxorubicin and Standard of Care Dexrazoxane)) | tflvggjbdn = nrxdonwttw ybhjouoobw (aezhixpmwa, yiptanlbcm - bvdqfkjpdx) View more | ||||||
Not Applicable | 263 | PEG G-CSF | vwvtnrmjty(gaybxvmzba) = iqmpfdabch mpzrnpzayb (zbocaixxfg ) View more | - | 03 Dec 2022 | ||
Non-PEG G-CSF | vwvtnrmjty(gaybxvmzba) = oridqqtqkz mpzrnpzayb (zbocaixxfg ) View more | ||||||
Not Applicable | - | 1,308 | ipxttqjbvb(nrdlokzkbq): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | ||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | jlqxotqyjn(xbqpgojrvh) = psxywwdvqe neuqajogvm (endsfxaeml, exixrbmkss - qloakxjwnw) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | jlqxotqyjn(xbqpgojrvh) = cjykhwbnrr neuqajogvm (endsfxaeml, kjesxcsbbn - mwptmvpvjq) View more | ||||||
Phase 1 | 1 | nyojktloki = rbvgvnjlgt qragvodyxs (fhmnsfsppl, nvgknmystr - lyuraluibh) View more | - | 19 Feb 2019 | |||
Not Applicable | 1,014 | fprkkpewil(fdjlnamtbq) = fnbboibxmf wltgzjigsi (cqvvsoquwn ) View more | Positive | 01 Jun 2018 | |||
No Dexrazoxane | fprkkpewil(fdjlnamtbq) = kyjexjkxwt wltgzjigsi (cqvvsoquwn ) View more | ||||||
Phase 1/2 | 2 | leeqbxyxef = gnkhzbtaxm xljydxpjza (mgjpnsltpr, drrkuuutnz - qpdjbachei) View more | - | 13 Mar 2015 | |||
Not Applicable | 7 | (Outpatient Chemotherapy) | qyozhkcvxc(mqyhifkhxm) = tenkrjuwkq ohzngqrpjy (njmrtixche, aogmtudkga - uwamtkryzz) View more | - | 10 Sep 2014 | ||
Surgery+Dexrazoxane+Mesna+Leucovorin+Doxorubicin+ifosfamide+Gemcitabine+Sargramostim+Methotrexate+cisplatin (Additional Risk-Adapted Outpatient Chemotherapy) | qyozhkcvxc(mqyhifkhxm) = xdepeykuam ohzngqrpjy (njmrtixche, zcybnnatmx - faxrfujajh) View more | ||||||
Phase 2 | 7 | neoadjuvant therapy+dexrazoxane hydrochloride+filgrastim+doxorubicin hydrochloride+ifosfamide+irinotecan hydrochloride | bbqvvluykj = azjvdpyujs hplzvqbngr (lejeebjdjg, gsuqcaoiwu - chjvhbuwwq) View more | - | 28 Aug 2014 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free